|
| 瑞舒伐他汀钙对急性冠脉综合征患者冠脉硬化程度及血浆NT-proBNP水平影响分析 |
| Rosuvastatin calcium in patients with acute coronary syndrome coronary sclerosis and impact analysis of plasma NT-proBNP levels |
| 投稿时间：2015-05-30 修订日期：2015-08-02 |
| DOI：10.3969/j.issn.1000-0399.2015.12.028 |
| 中文关键词: 急性冠脉综合征 瑞舒伐他汀 冠脉硬化 氨基末端脑利钠肽前体 |
| 英文关键词: Acute coronary syndrome Rosuvastatin Coronary sclerosis N-terminal pro-brain natriuretic peptide |
| 基金项目: |
|
| 摘要点击次数: 1837 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨瑞舒伐他汀钙对急性冠脉综合征(ACS)患者冠脉硬化程度及血浆氨基末端脑利钠肽前体(NT-proBNP)表达水平的影响.方法 采用随机数字法,将122例ACS患者分为观察组(瑞舒伐他汀钙)及对照组(阿伐他汀钙),每组61例.比较治疗4、8、16周时两组患者血脂水平及NT-proBNP、超敏C反应蛋白(Hs-CRP)表达水平差异,并对两组治疗效果及并发症发生情况进行比较.结果 治疗16周时,观察组患者三酰甘油、低密度脂蛋白胆固醇、总胆固醇水平低于对照组,且高密度脂蛋白胆固醇水平高于对照组,差异有统计学意义(P<0.05);同时,治疗周期内,两组患者不同治疗时期下NT-proBNP、Hs-CRP表达水平差异有统计学意义(P<0.05),且观察指标均与时间存在交互作用(FNT-proBNP=5.71,FHs-CRP=5.34);观察组患者治疗总有效率为86.88%,显著高于对照组(P<0.05),但两组患者不良反应发生率差异无统计学意义(P>0.05).结论 瑞舒伐他汀钙能有效改善ACS患者机体血脂水平,降低NT-proBNP及Hs-CRP表达水平,提高总体治疗效果,具有较高的临床应用价值. |
| 英文摘要: |
| Objective To investigate the impact of rosuvastatin calcium in patients with coronary sclerosis and plasma NT-proBNP level of expression of acute coronary syndrome. Methods A total of 122 cases of acute coronary syndrome patients diagnosed were randomized into the study group (rosuvastatin calcium) and control group (atorvastatin calcium), with 61 cases in each group. Two groups of patients were compared in terms of lipid levels and NT-proBNP, Hs-CRP expression level in 4, 8 and 16 weeks time, and the effects of treatment, and complications were compared as well. Results In 16 weeks of treatment, LDL-C, level of TC level decrease were lower, and HDL-C level was higher in TG observation group compared with those of the control group, and the difference was statistically significant (P<0.05); at the same time, within the treatment period, the difference in NT-proBNP, Hs-CRP expression levels in two groups of patients with different treatment period was statistically significant (P<0.05), and the observed indicators were interacted with time (FNT-proBNP=5.71,FHs-CRP=5.34). In addition, the observation group's total effective rate was 86.88%, significantly higher than that of the control group (P<0.05), but there was no significant difference between the two groups with respect to the incidence of adverse reactions(P>0.05). Conclusion Rosuvastatin calcium can improve the body blood lipid levels, lower NT-proBNP and Hs-CRP expression levels and improve overall treatment effect, with a high clinical value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
